- Home
- AGMB vs IDR Comparison
AGMB vs IDR Comparison
Compare AGMB & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMB | IDR |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.9M | 671.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AGMB | IDR |
|---|---|---|
| Price | $10.49 | $39.11 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 162.1K | ★ 329.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 70.15 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $42,406,253.00 |
| Revenue This Year | N/A | $25.52 |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | $33.16 |
| Revenue Growth | N/A | ★ 64.59 |
| 52 Week Low | $9.00 | $12.25 |
| 52 Week High | $17.45 | $54.70 |
Technical Indicators
Market Signals| Indicator | AGMB | IDR |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 62.46 |
| Support Level | $9.71 | $38.13 |
| Resistance Level | $14.55 | $41.08 |
| Average True Range (ATR) | 1.42 | 2.29 |
| MACD | 0.03 | 1.18 |
| Stochastic Oscillator | 33.11 | 99.69 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.